β-基酸盐:对于各种肝脏疾病来说,这是一个重要的治疗点
Ke Li1, Wen-Hong Wang1, Jia-Bin Wu1
1Key Lab of Exercise and Health Sciences of Ministry of Education, Shanghai University of Sport, Shanghai 200438, China; Shanghai Key Lab of Human Performance, Shanghai University of Sport, Shanghai 200438, China.
概括
β-基酸盐 (β-HB) 通过作为能量来源和信号分子,为肝脏疾病提供治疗潜力. 营养策略,如性饮食和禁食,可能会保护肝脏.
科学领域:
- 生物化学 生物化学
- 代谢疾病 代谢疾病
- 肝病学 肝病学是一种肝病学.
背景情况:
- β-基酸盐 (β-HB) 是肝脏中产生的关键体,在低血糖或糖原耗尽期间作为替代能源.
- 最近的研究强调了β-HB作为信号分子和表观遗传调节者的作用,影响各种生理和病理过程.
- 肝脏的中心代谢作用使得β-HB在肝脏疾病中的功能成为一个重要的研究领域.
研究的目的:
- 审查β-HB对肝脏疾病的治疗作用.
- 阐明β-HB在肝脏疾病中的作用的潜在机制.
- 探索肝脏保护和疾病治疗的营养策略.
主要方法:
- 关于β-HB和肝脏疾病的研究文献综述.
- 分析β-HB作为能量替代物和信号分子的作用.
- 检查内源性症 (禁食,热量限制,饮食,运动) 和外源性β-HB补充剂.
主要成果:
- 在各种肝脏疾病中,β-HB显示出治疗潜力.
- 机制包括β-HB在能量代谢和表观遗传调节中的作用.
- 营养干预措施,如性饮食和禁食,显示出保护肝脏的前景.
结论:
- 在代谢性肝病中,β-HB具有显著的治疗前景.
- 了解β-HB的信号通路对于开发向治疗至关重要.
- 辅助营养疗法,包括性饮食和禁食,是管理肝脏健康的可行策略.
相关概念视频
Liver Physiology
647
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
647
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
699
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
699
Hepatic Drug Excretion: Enterohepatic Cycling
1.6K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.6K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
61
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
61
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
174
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
174


